REMARKS

Claims 1-139 stand ready for examination. The present Office Action states that the reply filed on November 4, 2002, is not fully responsive to the prior Office Action because the Applicants failed to elect a single enhanced combination of one DNA topoisomerase I inhibitor with one COX-2 inhibitor.

RECEIVED

TECH CENTER 1600/2300

ELECTION

In response to the restriction, Applicants elect irinotecan from the list of DNA topoisomerases, and celecoxib from the list of COX-2 inhibitors for purposes of examination. Claims 1-5, 7-12, 14, 40-51, 53-58, 60, 86-97, 99-104, 106, 132-139 are readable thereon.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

Date: March 17, 2003

James M. Warner

Attorney for Applicants

Reg. No. 45,199

314-274-3642 (St. Louis)

Pharmacia Corporation Corporate Patent Department 575 Maryville Centre Dr. St. Louis, MO 63141